Bacillus Subtilis in Parkinson's Disease

Launched by UNIVERSITY OF EDINBURGH · Jun 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a supplement called Bacillus Subtilis on people with Parkinson's disease. Researchers want to see if taking this supplement can change certain markers in the body related to Parkinson's and whether it is safe and acceptable for regular use. The trial is currently looking for participants who are over 50 years old, have been diagnosed with Parkinson's for at least a year, and have been stable on their medication for the last three months.

To be part of this study, you would need to be able to provide consent and meet specific health criteria, such as not using certain probiotic foods or antibiotics recently. If you join the trial, you can expect to help researchers understand more about how this supplement might work for Parkinson's disease, while also being closely monitored for any side effects. This study could potentially lead to new ways to support people living with Parkinson's.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of Parkinson's disease
• • Able to provide written informed consent
• • Over 50 years old
• • Motor symptom duration over 12 months
• • Stable dopaminergic medication regime for at least 3 months
• Exclusion Criteria:
• • Use of probiotic supplements and probiotic-fortified foods (such as probiotic drinks and yoghurts) within past 3 months
• • Use of antibiotics within past 3 months
• • Previous gastrointestinal surgery or chronic organic bowel disorder
• • History of clinically significant motor fluctuations
• • History of postural instability or falls
• • Current smoker
• • Known or suspected allergy to probiotics
• • Regular use of antacids, proton pump inhibitors, laxatives or anti-diarrheal drugs
• • Use of hypoglycaemic or diabetes drugs
• • Participation in clinical trial of investigational medicinal product within past 3 months
• • Co-morbidities or other factors that, in the opinion of the investigator, make the patient unlikely to comply with study protocol